U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K/A
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934
 
Date of Report (Date of earliest event reported): November 18, 2016
 
HH BIOTECHNOLOGY HOLDINGS COMPANY
(Exact name of registrant as specified in its charter)
 
0-23015
(Commission File No.)
 
Nevada
(State or other jurisdiction of
incorporation or organization)
 
87-0450232
(IRS Employer Identification No.)
 
 
C Site 25-26F President Building, No. 69 Heping North Street
Heping District, Shenyang 110003, Peoples Republic of China
(Address of principal executive offices)
 
0086-24-22813888
(Registrant’s telephone number)
 
Not applicable
(Former Name or Former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
 
[ ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
 
 
Item 5.02                        Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
On November 18, 2016, the Board of Directors of HH Biotechnology Holdings Company (the “Company”) adopted resolutions increasing the number of directors on the board to five and electing Mr. Charles T. Mathews as a director to fill the new directorship, and Mr. Mathews was assigned as the chairman of the Compensation Committees of the Board of Directors of the Company.
 
For service on the Board, Mr. Mathews will receive a quarterly fee of $10,000 and reimbursement of expenses.
 
 
 
 
 
 
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
HH Biotechnology Holdings Company
 
 
 
 
 
Date: November 21, 2016 
By:  
/s/  Sheng Jiang
 
 
 
Sheng Jiang  
 
 
 
Chief Executive Officer  
 

 
 
 
 
 
 
 
HH Biotechnology (CE) (USOTC:HHBT)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more HH Biotechnology (CE) Charts.
HH Biotechnology (CE) (USOTC:HHBT)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more HH Biotechnology (CE) Charts.